Matthew Winton - 17 Nov 2025 Form 4 Insider Report for CervoMed Inc. (CRVO)

Reporting relationship: Chief Commercial and Business
Issuer ticker: CRVO
Reported as of: 17 Nov 2025
Net transaction value: +$41,430
SEC form: 4
Accepted by SEC: 19 Nov 2025, 07:46:15 UTC
Prior SEC filing: 17 Nov 2025
Next SEC filing: 13 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ William R. Elder, attorney-in-fact for the Reporting Person

Key filing fact

Matthew Winton filed Form 4 for CervoMed Inc. (CRVO) on 19 Nov 2025.

Key facts

This page summarizes Matthew Winton's Form 4 filing for CervoMed Inc. (CRVO).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 19 Nov 2025, 07:46.

Change

Previous filing in this sequence was filed on 17 Nov 2025.
Current net transaction value: +$41,430.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001971400 Primary reporting owner

Winton Matthew

Relationship: Chief Commercial and Business
Address: C/O CERVOMED INC., 20 PARK PLAZA, SUITE 424, BOSTON
Signature: /s/ William R. Elder, attorney-in-fact for the Reporting Person
Signature date: 19 Nov 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CRVO transaction

Common Stock

Purchase

Transaction value: $29,505
Shares: +3,500
Change %: +35%
Price: $8.43
Shares after: 13,500
Date: 17 Nov 2025
Ownership: Direct
Footnotes: F1

CRVO transaction

Common Stock

Purchase

Transaction value: $11,925
Shares: +1,500
Change %: +11%
Price: $7.95
Shares after: 15,000
Date: 18 Nov 2025
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Shares purchased in open-market transactions.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .